Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study

Wongchenko, Matthew J.; Miles, D; Kim, S.B.; Xu, Na; Amler, Lukas C.; Yan, Yuzhao; Simmons, Brian; McNally, Virginia; Brufsky, AM

doi:10.1016/s0959-8049(16)33041-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Again, the addition of cobimetinib to first-line paclitaxel did not demonstrate significant improvement in mPFS 85 . Interestingly, the biomarker explorative analysis showed a potential immunomodulatory effect of cobimetinib in increasing the immune infiltration within TME 86 . Consistently, the part 2 of COLET study was designed to test the combination of cobimetinib, nab-paclitaxel and atezolizumab, with preliminary signs of activity in the PD-L1-positive population 87 .…”

Section: Introductionmentioning

confidence: 99%

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

et al. 2020

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across TNBC subtypes, prompting the implementation of biomarker-driven therapeutic approaches. However, biomarker-based treatments as well as immune checkpoint inhibitor-based immunotherapy have provided contrasting and limited results so far. Accordingly, a better characterization of the genomic and immune contexture underpinning TNBC, as well as the translation of the lessons learnt in the metastatic disease to the early setting would improve patients’ outcomes. The application of multi-omics technologies, biocomputational algorithms, assays for minimal residual disease monitoring and novel clinical trial designs are strongly warranted to pave the way toward personalized anticancer treatment for patients with TNBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…63 In the phase 2 COLET trial, the MEK inhibitor cobimetinib was added to first-line paclitaxel for the treatment of patients with mTNBC but did not improve PFS. 64 However, an exploratory biomarker analysis suggested that cobimetinib increased immune infiltration within the tumor microenvironment 65 and, as such, a second part of the COLET trial began enrolling patients to be treated with a triplet of atezolizumab 840 mg IV on day 1 and 15, cobimetinib 60 mg PO on days 3-23, and paclitaxel IV 80 mg/m 2 (cohort 2) or nab-paclitaxel IV 100 mg/m 2 (cohort 3) on days 1, 8, and 15 of 28-day cycles. Data for 62 evaluable patients are presented in Table 1.…”

Section: Icis Plus Mek Inhibitorsmentioning

confidence: 99%

Impact of emerging clinical trends on overall cost of care and the role of the managed care pharmacist

Tombleson¹

2021

Am J Manag Care

View full text Add to dashboard Cite

Managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in scientific advances for combination therapies in the treatment of metastatic triple-negative breast cancer. Accreditation StatementPharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-127-H01-P. The activity is available for CE credit through October 15, 2021.Obtaining Credit: Participants must read the article and complete the online posttest and an online evaluation and request for credit. Detailed instructions on obtaining CE credit are included at the end of this activity.

show abstract

Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study

Cited by 2 publications

References 0 publications

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Impact of emerging clinical trends on overall cost of care and the role of the managed care pharmacist

Contact Info

Product

Resources

About